Efficacy of combined treatment with human adipose tissue stem cell‐derived exosome‐containing solution and microneedling for facial skin aging: A 12‐week prospective, randomized, split‐face study

Abstract Background Studies have reported promising results of mesenchymal stem cell therapies for skin aging. However, in the use of mesenchymal stem cells, some drawbacks including rarely possible tumorigenicity and low engraftment rates have limited their widespread clinical use. Adipose tissue stem cell‐derived exosomes (ASCEs) are emerging as effective cell‐free therapeutic agents. Aims It was evaluated the clinical efficacy of combining the application of human ASCE‐containing solution (HACS) with microneedling to treat facial skin aging. Methods A 12‐week, prospective, randomized, split‐face, comparative study was conducted. Twenty‐eight individuals underwent three treatment sessions separated by 3‐week intervals and were followed up for 6 weeks after the last session. At each treatment session, HACS and microneedling were administered to one side of the face, and normal saline solution and microneedling were administered to the other side as a control. Results The Global Aesthetic Improvement Scale score was significantly higher on the HACS‐treated side than on the control side at the final follow‐up visit ( p = 0.005). Objective measurements obtained by different devices including PRIMOS Premium, Cutometer MPA 580, Corneometer CM 825, and Mark‐Vu confirmed greater clinical improvements in skin wrinkles, elasticity, hydration, and pigmentation on the HACS‐treated side than on the control side. The results of the histopathological evaluation were consistent with the clinical findings. No serious adverse events were observed. Conclusions These findings demonstrate that combined treatment using HACS and microneedling is effective and safe for treating facial skin aging.